UNITED THERAPEUTICS Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $522.57 ($511.58–$531.12, $4.96M total) across 18 trades on 2026-08-27 under a Rule 10b5-1 trading plan.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.28 ($514.64–$521.48, $4.91M total) across 8 trades on 2026-08-26 under a Rule 10b5-1 trading plan.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.71 ($516.12–$520.50, $4.92M total) across 6 trades on 2026-08-25 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 4 news stories mentioning UTHR (UNITED THERAPEUTICS Corp). Coverage has skewed bullish: 2 bullish, 1 neutral, and 1 bearish.
Recent UTHR coverage spans insider activity, financial news and regulation.
In the last 30 days, UTHR insiders filed 247 SEC Form 4 transactions — no purchases and 247 sales ($112.0M). The most active reporter was ROTHBLATT MARTINE A, Chairperson & CEO, with 230 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal confidence concerns, potentially pressuring the stock short term.
Large insider sell may pressure the stock short term.
Insider sale by the CEO may signal reduced confidence or portfolio rebalancing.
Potential negative sentiment as insider reduces stake; modest impact on price.
Large insider sell may signal confidence concerns, potentially pressuring the stock lower.
alphai scores every news story that mentions UTHR with an AI model for sentiment and relevance, and aggregates insider trades from UNITED THERAPEUTICS Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $522.57 ($511.58–$531.12, $4.96M total) across 18 trades on 2026-08-27 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.28 ($514.64–$521.48, $4.91M total) across 8 trades on 2026-08-26 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $517.71 ($516.12–$520.50, $4.92M total) across 6 trades on 2026-08-25 under a Rule 10b5-1 trading plan.
1 min readAn insider of United Therapeutics sold shares worth $4.86 million, according to a recent SEC filing. The company's stock is currently trading at $517.42, with a 5-day change of -0.22% and a year-to-date change of -1.67%.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $511.97 ($509.41–$513.35, $4.86M total) across 5 trades on 2026-08-24 under a Rule 10b5-1 trading plan.
1 min readROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $518.39 ($512.71–$527.71, $4.92M total) across 15 trades on 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readThe FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.
2 min readUnited Therapeutics (UTHR) completed enrollment of 754 patients in its phase 3 TETON-PPF trial for nebulized Tyvaso in progressive pulmonary fibrosis. This positions Tyvaso for potential label expansion and complements ongoing regulatory efforts for idiopathic pulmonary fibrosis. The company reported Q2 2026 net income of $333.0 million and a $2.0 billion share repurchase program, with analysts projecting 2029 revenue of $5.0 billion and earnings of $2.3 billion.
2 min readAn insider of United Therapeutics sold shares worth $4.3 million, according to a recent SEC filing. The company's stock is trading at 513.12 USD, with a 5-day change of -1.51%.
1 min readUnited Therapeutics (UTHR) CEO Martine A. Rothblatt exercised 9,500 stock options at $135.42 and sold 9,500 shares at $518–$525 each on August 20, 2026, under a 10b5-1 plan. The sale generated $4.95M in gross proceeds. Rothblatt retains 94,410 options and 40,513 shares directly.
1 min read
